Suzanne Ildstad, Director at Talaris Therapeutics, Inc. (TALS), sold 58,939 shares at $2.53 ($149K) on 2023-06-06, disclosed to the SEC on 2023-06-07.
Scheduled sale ($149k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.52 | 7,841 | $20K | 13.3% |
| 2 | $2.53 | 25,549 | $65K | 43.4% |
| 3 | $2.53 | 25,549 | $65K | 43.4% |
| Total | $2.53 avg | 58,939 | $149K | 100% |
| Filing → |
| TALS | SELL | 2023-06-05 | $80K | — | Filing → |
| TALS | SELL | 2023-04-25 | $35K | — | Filing → |
| TALS | SELL | 2023-04-21 | $266K | — | Filing → |